Almost two-thirds of the children who died with H1N1 had epilepsy, cerebral palsy or other neurodevelopmental conditions.
About one in 13 H1N1 deaths in the United States have been children, and most of them have been of school age, according to the Centers For Disease Control and Prevention.
More than 40 U.S. children have died from the virus since it was first identified in here in April.
The CDC has found some differences in the pediatric death toll from H1N1 as compared with seasonal flu, including:
• Normally, half or more of the children who die from flu are age 4 and younger. More than 80% of the children with H1N1 were age 5 or older.
• Almost two-thirds of the children who died with H1N1 had epilepsy, cerebral palsy or other neurodevelopmental conditions. In a previous flu season, only one-third of pediatric deaths had those conditions.
• Bacterial co-infections were a big danger and were blamed in most of the deaths of otherwise healthy children.
The general consensus is that there are two main issues: getting information about the virus to high-risk populations; and addressing those who may be sick as well as the “worried well.”
“Such an effort must be undertaken in a way that is supportive but does not cause alarm,” says Alexandra Drane, president and co-founder of Eliza Corp., who recently attended a summit on H1N1 preparedness in Washington, D.C.
“Despite all the attention we’ve spent on preparing for potential H1N1 outbreaks, we must all stay vigilant in our efforts to prevent seasonal flu, especially among populations who may not be as vulnerable to the H1N1 virus,” Drane tells Managed Healthcare Executive.
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Conversations with Perry and Friends: Saar Mahna, J.D., MBA
July 7th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the "Conversations with Perry and Friends" podcast. In this episode, Cohen speaks with Saar Mahna, J.D., MBA, CEO and founder of Banjo Health, an artificial intelligence company focused on prior authorization.
Listen
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
FDA Accepts Tabelecleucel BLA; Priority Review Granted for Post-Transplant Disease Therapy
July 24th 2025The FDA has accepted the resubmitted BLA for tabelecleucel (tab-cel), intended for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).
Read More